Products
Voxilaprevir is commercially available as film-coated tablets in fixed combination with sofosbuvir and velpatasvir (Vosevi). It was approved in the United States, many countries, and the EU in 2017.
Structure and properties
Voxilaprevir (C40H52F4N6O9S, Mr = 868.9 g/mol)
Effects
Voxilaprevir has antiviral properties. The effects are due to noncovalent and reversible inhibition of the viral enzyme NS3/4A protease. It has a half-life of 33 hours.
Indications
For combination therapy of chronic hepatitis C after failure of prior therapy with direct antiviral agents.
Dosage
According to the SmPC. Tablets are taken once daily with a meal.
Contraindications
For complete precautions, see the drug label.
Interactions
Voxilaprevir is a substrate of BCRP, P-glycoprotein, OATP1B1, OATP1B3, and CYP3A4.
Adverse effects
The most common potential adverse effects of combination therapy include headache, diarrhea, and nausea.
